JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Omeros Corp

Suletud

SektorTervishoid

7.65 -0.78

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.59

Max

7.91

Põhinäitajad

By Trading Economics

Sissetulek

8M

-25M

Kasumimarginaal

-8,121.359

Töötajad

202

EBITDA

9.3M

-26M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+71.63% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2025

Turustatistika

By TradingEconomics

Turukapital

284M

561M

Eelmine avamishind

8.43

Eelmine sulgemishind

7.65

Uudiste sentiment

By Acuity

18%

82%

29 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Omeros Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. okt 2025, 15:36 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15. okt 2025, 13:27 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

15. okt 2025, 12:33 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15. okt 2025, 12:32 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15. okt 2025, 12:32 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15. okt 2025, 12:32 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

Võrdlus sarnastega

Hinnamuutus

Omeros Corp Prognoos

Hinnasiht

By TipRanks

71.63% tõus

12 kuu keskmine prognoos

Keskmine 13.13 USD  71.63%

Kõrge 20 USD

Madal 6.269 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Omeros Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.265 / 7.49Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

29 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat